Published in Antivir Ther on December 01, 2004
Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis (2006) 5.90
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. BMC Infect Dis (2010) 1.64
Antiretroviral treatment of HIV infected adults. BMJ (2006) 1.13
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 1.12
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods (2009) 1.06
Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis (2009) 1.00
Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther (2009) 0.90
Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One (2007) 0.84
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape. BMC Bioinformatics (2010) 0.79
German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. Eur J Med Res (2009) 0.78
Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. J Clin Microbiol (2012) 0.78
HIV-1 mutational pathways under multidrug therapy. AIDS Res Ther (2011) 0.77
Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients. Can J Infect Dis Med Microbiol (2006) 0.75
Retrospective analysis of the HIV-1 reverse transcriptase inhibitors' resistance in Silesia, Poland. Med Sci Monit (2011) 0.75
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Segmental aneuploidy and the genetic gross structure of the Drosophila genome. Genetics (1972) 22.68
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet (1998) 14.31
Why do people sue doctors? A study of patients and relatives taking legal action. Lancet (1994) 10.79
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr (2012) 10.61
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 7.15
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
HIV-1 nomenclature proposal. Science (2000) 6.61
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. J Clin Microbiol (2001) 6.40
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol (2001) 5.87
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol (1978) 5.22
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Epidemiological basis for clinical diagnosis of childhood malaria in endemic zone in West Africa. Lancet (1991) 5.11
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med (1998) 4.92
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med (1993) 4.88
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Searching MEDLINE for randomized clinical trials involving care of the newborn. Pediatrics (1989) 4.79
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
EXPERIMENTAL HYPOSTHENURIA. J Clin Invest (1939) 4.64
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res (1995) 4.17
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Conservation of secretion pathways for pathogenicity determinants of plant and animal bacteria. Trends Microbiol (1993) 3.85
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 3.43
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
A formalin-inactivated whole SIV vaccine confers protection in macaques. Science (1989) 3.37
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol (1993) 3.34
Megaplasmids in the plant-associated bacteria Rhizobium meliloti and Pseudomonas solanacearum. J Bacteriol (1982) 3.33
Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol (1992) 3.30
Diabetes mellitus in American (Pima) Indians. Lancet (1971) 3.30
Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection (1991) 3.29
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
[AIDS treatment in Africa: the risk of antiretroviral resistance]. Ned Tijdschr Geneeskd (2007) 3.15
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Treatment of SARS with human interferons. Lancet (2003) 3.10
Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis (1999) 3.04
Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat (2009) 3.02
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Partitioning of C-photosynthate, and long distance translocation of amino acids in preflowering and flowering, nodulated and nonnodulated soybeans. Plant Physiol (1979) 2.99
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Postaxial acrofacial dysostosis syndrome. J Pediatr (1979) 2.93
Evidence of recombination among enteroviruses. J Virol (1999) 2.92
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
Recent observations on the serology of syphilis. Br J Vener Dis (1980) 2.90
Phase I cancer trials. A collusion of misunderstanding. Hastings Cent Rep (2000) 2.90
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
IUSTI: 2008 European Guidelines on the Management of Syphilis. Int J STD AIDS (2009) 2.85
Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type III. Lancet (1985) 2.84
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84